Please login to the form below

Not currently logged in
Email:
Password:

BMS' brivanib fails first-line liver cancer trial

Second major trial failure means uncertain future for drug

The future of Bristol-Myers Squibb's investigational cancer drug brivanib is hanging in the balance after it failed a phase III trial in advanced hepatocellular carcinoma (HCC).

Brivanib (formerly BMS-582664) failed to meet the primary endpoint of non-inferiority to Bayer/Onyx Pharmaceuticals' Nexavar (sorafenib) as a first-line treatment for HCC, a form of liver cancer, in patients who had not received any prior treatment for the disease.

This is not the first disappointment in brivanib's development programme. In December, 2011, BMS reported that the drug was unable to improve overall survival in another trial in HCC involving patients whose cancer had progressed despite earlier treatment with Nexavar.

Ahead of that trial failure analysts had predicted sales for brivanib of around $250m to $450m a year by 2020.

BMS said in a statement that it is "considering options" for the ongoing development of brivanib, which is an oral inhibitor of vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR).

Previously, the company had said it planned to file for approval of brivanib in the US and Europe this year.

The BRISK-FL study in HCC is one of a number being carried out on brivanib, which is also being studied as an adjuvant therapy in HCC, as well as in renal cell carcinoma, colorectal cancer and cervical cancer.

In the past, BMS has identified brivanib as one of five late-stage compounds it is hoping will help it plug the revenue gap now that blockbuster anticoagulant Plavix (clopidogrel) is starting to be affected by generic competition.

The company also experienced a late-stage pipeline disappointment recently when the FDA asked for more information on Eliquis (apixaban), a novel anticoagulant in development as a preventative treatment for stroke and systemic embolism in patients with non-valvular atrial fibrillation partnered with Pfizer.

Commenting on the outcome of the latest study, BMS' senior vice president of global development and medical affairs, Brian Daniels, said: "The treatment options for patients with advanced HCC are limited, and we are disappointed that the primary endpoint was not met."

20th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
11 London

Fast-acting communications agency creating content for anything to do with health, in any medium – digital or offline. We develop...

Latest intelligence

If you needed an organ transplant, would you have one?
Lauren Packer discusses the worsening problem in the UK with an imbalance between the number of organs needed, and the number of those being donated....
Why tugging at our heartstrings is no longer enough to make us open our purses
Charlotte Shyllon (Director and Partner) and Maren Thurow (Senior Account Executive), discuss the highly emotive Make a Child Cry campaign video from Doctors of the World (Médecins du Monde)....
quantify_messages.png
Exploring full potential of e-detailing data
Today’s high quality e-detailing data can create better quality conversations with healthcare professionals and result in improved access and relationships....

Infographics